ABOS

In the past six months, Acumen Pharmaceuticals announced a private placement of common stock to advance its Enhanced Brain Delivery program. The company reported its third-quarter 2025 and full-year 2025 financial results, highlighting progress in its Phase 2 trial and EBD program. Updates on the ALTITUDE-AD trial were provided, with topline results anticipated in late 2026. Acumen participated in healthcare conferences, highlighting its EBD technology and recruitment strategies. The stock price increased significantly year-over-year but has shown volatility, with short interest increasing recently.